South Africa caps exenatide prescribing to 20 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 3 of 33 of this archive, newest first.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
Reported from the analysis, not from a warning notice.
A proper account of an operation that existed, and of what closing it cost.
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Reported from the analysis, not from a warning notice.
A proper account of an operation that existed, and of what closing it cost.
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
A proper account of an operation that existed, and of what closing it cost.
A proper account of an operation that existed, and of what closing it cost.
A proper account of an operation that existed, and of what closing it cost.
A proper account of an operation that existed, and of what closing it cost.